Sympathetic Overactivity: The Driver of Hypertension in Young Indians

Hypertension is rapidly affecting younger age groups, creating decades of cumulative exposure to elevated blood pressure and substantially increasing lifetime cardiovascular risk. In a recent urban Indian study, hypertension was present in 24.8% of adults aged 18–35 years, with a higher prevalence among men (28.3%) than women (20.4%). ¹ The nationwide BEAT-HTN India survey further reported hypertension in 29.8% of 41,370 adults under 54 years and a mean resting heart rate of 83.9 bpm, highlighting a considerable burden of sympathetic overactivity among young and middle-aged Indian hypertensive patients. ² This elevated heart-rate phenotype highlights sympathetic overactivity as a plausible underlying mechanism linking contemporary cardiometabolic stressors with early-onset hypertension and accelerated cardiovascular risk.

Sympathetic Overactivity: Contributor of Early Hypertension Development & Progression in Young

The sympathetic nervous system (SNS) plays a central role in maintaining blood pressure homeostasis through integrated regulation of cardiac output, vascular tone, and renal function. Persistent sympathetic overactivity (SO) disrupts this physiological balance and is a key neurogenic mechanism underlying early hypertension. Enhanced sympathetic outflow increases heart rate and myocardial contractility, promotes peripheral vasoconstriction, and stimulates renal sympathetic activity, resulting in increased sodium and water reabsorption, reduced renal blood flow, and activation of the renin–angiotensin–aldosterone system (RAAS). Together, these haemodynamic and neuro-hormonal alterations sustain blood pressure elevation and promote development and progression of hypertension. Contemporary lifestyle factors including obesity, psychosocial stress, physical inactivity, poor sleep, and excess dietary sodium further amplify sympathetic activation, making SO an important therapeutic target in young hypertensive individuals. ^{3, 4} (Figure 1)

Figure 1: Sympathetic Overdrive in Young Hypertension: Pathophysiological Interactions and Sequels

Abbreviations: LV – Left Ventricular; RAAS - renin–angiotensin–aldosterone system

Hypertension with Sympathetic Overactivity: Clinical Sequels

Sympathetic overactivity is highly prevalent and clinically relevant in Indian hypertensive patients. In a Pan-India study of 1,514 newly diagnosed hypertensive patients, 945 (62.4%) had symptoms suggestive of sympathetic overactivity, indicating that nearly six in ten patients may exhibit this neurogenic phenotype. The cohort also had a high mean heart rate of 90 bpm, with a significant association observed between sympathetic overactivity and heart rate. ⁵ Persistent sympathetic activation increases heart rate, cardiac workload, peripheral vascular resistance, and importantly, blood-pressure variability.

Over time, it contributes to endothelial dysfunction, arterial stiffness, vascular remodeling, and left ventricular hypertrophy (LVH), while renal sympathetic activation sustains sodium retention and RAAS activity. These disruptive sequels arising from sympathetic overactivity may accelerate target-organ damage and increase the risks of coronary artery disease, heart failure, stroke, arrhythmias, and sudden cardiac death.

Telmisartan - Metoprolol: Targeting Hypertension and Heart Rate in Young Hypertensives

In hypertensive patients with sympathetic overactivity, targeting both the RAAS and sympathetic nervous system offers a complementary therapeutic strategy.

• Together, dual RAAS–SNS modulation addresses both elevated blood pressure and heart rate, two independent determinants of cardiovascular risk. Recognizing elevated resting heart rate (>80 bpm) as a surrogate marker of sympathetic overactivity, the European Society of Hypertension (ESH) guidelines recommend incorporating heart rate phenotype into individualized antihypertensive treatment decisions.

• Telmisartan inhibits angiotensin II mediated vasoconstriction, aldosterone secretion, and sympathetic facilitation, while metoprolol provides selective β₁-blockade, reducing heart rate, myocardial oxygen demand, cardiac output, and renin release. ^{6, 7}

• Telmisartan may also provide metabolic benefits beyond blood pressure reduction through partial PPAR-γ modulation, with evidence suggesting improvement in hepatic steatosis and histological activity in MASLD, particularly relevant to young hypertensive patients with cardiometabolic dysfunction. ⁸

• It is noteworthy that the recent FAERS pharmacovigilance data suggest a comparatively favourable respiratory safety profile for metoprolol among β-blockers, supporting its consideration in hypertensive patients with coexisting obstructive airway disease. ⁹

Telmisartan - Metoprolol Combination in Young Hypertension Patients: Recent Clinical Evidence

Indian Clinical Consensus for Management of Young Hypertension: A nationwide Indian study integrating a clinical survey including 828 clinicians with expert panel discussions including 342 senior doctors evaluated management strategies for hypertension with sympathetic overactivity and obesity. Overall, 66% clinicians preferred telmisartan with a cardioselective β-blocker for patients with sympathetic overactivity, while 62% specifically favoured the telmisartan–metoprolol combination to control sympathetic overactivity. About 54% clinicians cited its potential to prevent structural and functional myocardial changes. ¹⁰ These findings are reflected in routine Indian practice, with the RECORD Registry identifying telmisartan–metoprolol as the most commonly prescribed ARB–β-blocker combination in India. ¹¹

Key Clinical Takeaways

• Elevated resting heart rate should be recognized as a practical surrogate of sympathetic overactivity in young hypertensive patients and incorporated into individualized treatment decisions. ⁶

• Sympathetic overactivity is not merely a marker of hypertension but an established driver of vascular remodeling, RAAS activation, and long-term cardiovascular risk. ^{3, 4}

• In young Indian patients with hypertension and sympathetic overactivity, therapeutic strategies should prioritize achieving both blood pressure and heart rate control to effectively address residual cardiovascular risk and improve long-term outcomes.

• Dual RAAS–SNS blockade with telmisartan–metoprolol FDC targets two complementary pathophysiological pathways, with Indian clinical evidence supporting its efficacy, safety, and wide clinical acceptance. ^{6, 7}

**Abbreviations: BP: Blood Pressure; HR: Heart Rate; BEAT-HTN: Burden, Epidemiology, and Trends of Hypertension; SNS: Sympathetic Nervous System; SOSA: Sympathetic Overactivity; RAAS: Renin–Angiotensin–Aldosterone System; ESH: European Society of Hypertension; FDC: Fixed-Dose Combination; ER: Extended Release; HCPs: Healthcare Professionals; ARB: Angiotensin II Receptor Blocker; CAD: Coronary Artery Disease; RECORD: REgistry on Current Patient PrOfiles and TReatment TrenDs in Hypertension; bpm: Beats Per Minute; PPAR-γ: partial peroxisome proliferator-activated receptor-γ